Intranasal sumatriptan: In adolescents with migraine

CNS Drugs

Volumn 19, Issue 4, 2005, Pages 335-343

  Curran, Monique P ^a   Evans, Hannah C ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUTORPHANOL; CLARITHROMYCIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; FLUNARIZINE; MONOAMINE OXIDASE INHIBITOR; NOSE SPRAY; PIZOTIFEN; PLACEBO; PROPRANOLOL; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; XYLOMETAZOLINE;

ADOLESCENCE; BURNING SENSATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; MIGRAINE; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TASTE DISORDER; VOMITING;

ADMINISTRATION, INTRANASAL; ADOLESCENT; HUMANS; MIGRAINE DISORDERS; SUMATRIPTAN;

EID: 17844364618     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519040-00006     Document Type: Review

References (29)

1. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994 Sep 24; 309: 765-9
2. Hämäläinen M, Jones M, Loftus J, et al. Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. Int J Clin Pract 2002 Nov; 56 (9): 704-9
3. Perry CM, Markham A. Sumatriptan: an updated review of its use in migraine. Drugs 1998 Jun; 55 (6): 889-922
4. Winner P, Rothner AD, Putnam DG, et al. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database. Headache 2003 May; 43 (5): 451-7
5. VanDenBrink AM, van den Broek RWM, de Vries R, et al. Human middle meningeal and coronary artery contraction to eletriptan and Sumatriptan [abstract no. III-F1-4]. Cephalalgia 1999 May; 19 (4): 398
6. VanDenBrink AM, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998 Jul 7; 98 (1): 25-30
7. Moore KHP, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of Sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997 Jun; 17 (4): 541-50
8. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992 Jun; 106 (2): 409-15
9. Burstein R. Deconstructing migraine headache into peripheral and central sensitisation. Pain 2001; 89: 107-10
10. Christensen ML, Mottern RK, Jabbour JT, et al. Pharmacokinetics of sumatriptan nasal spray in adolescents. J Clin Pharmacol 2003 Jul; 43 (7): 721-6
11. Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998 Apr; 6 (2): 99-104
12. Fuseau E, Petricoul O, Moore KHP, et al. Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002; 41 (11): 801-11
13. GlaxoSmithKline (US). Imitrex® (sumatriptan) nasal spray: prescribing information 2004 [online]. Available from URL: http://www.gsk.com [Accessed 2004 Sep 24]
14. GlaxoSmithKline (UK). Imigran® 10mg and 20mg nasal spray: prescribing information 2003 [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2003 Sep 18]
15. 1B/1D receptor agonists [abstract]. Headache Q 2001; 12 (1): 45
16. Moore KHP, McNeal S, Britto MR, et al. The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ ethinyl estradiol 0.035 mg in healthy volunteers. Clin Ther 2002 Nov; 24 (11): 1887-901
17. Moore KHP, Leese PT, McNeal S, et al. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers. Clin Ther 2002; 24 (4): 583-94
18. Srinivasu P, Rambhau D, Rao BR, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol 2000 Jan; 40 (1): 99-104
19. Scott AK, Walley T, Breckenridge AM, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991 Nov; 32 (5): 581-4
20. Van Hecken AM, Depré M, De Schepper PJ, et al. Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol 1992 Jul; 34(1): 82-4
21. Fowler PA, Lacey LF, Keene ON, et al. Effect of prophylactic migraine medications on the pharmacokinetic and pharmacodynamic profiles of sumatriptan. Cephalalgia 1991 Jun; 11 Suppl. 11: 228-9
22. Vachharajani NN, Shyu WC, Nichola PS, et al. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration. Cephalalgia 2002 May; 22 (4): 282-7
23. Winner P, Rothner D, Webster C, et al. Randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in adolescent migraineurs. Neurology 2004; 62 Suppl. 5: 182
24. Ahonen K, Hamalainen ML, Rantala H, et al. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004 Mar 23; 62 (6): 883-7
25. Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000 Nov; 106 (5): 989-97
26. Winner P, Rothner AD, Webster C, et al. Overall efficacy of sumatriptan nasal spray in adolescent migraineurs: pooled results from US placebo-controlled trials [abstract]. Plus poster presented at the 46th Annual Scientific Meeting of the American Headache Society 2004 Oct 10-13; Vancouver. Headache 2004; 44 (5): 481-2
27. Rothner AD, Winner P, Nett R, et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 2000 Dec; 22 (12): 1533-46
28. Natarajan S, Jabbour JT, Webster CJ, et al. Long-term tolerability of sumatriptan nasal spray in adolescent patients with migraine. Headache 2004; 44: 969-77
29. Woodman R. Glaxo rolls out migraine drug imigran nasal spray for adolescents in Europe 2003 [online]. Available from URL: www.medscape.com [Accessed 2003 Sep 15]